Programmed Cell Death 1 checkpoint inhibitors as cancer therapies

Qifan Wen *

Department of Biology, Colby College, Waterville, Maine

* Corresponding Author Email: qwen23@colby.edu

Abstract. CD279 protein, also well known as the programmed-cell-death-protein-1 or PD-L1, is identified as a surface protein found primarily on T lymphocytes, and B cells, serving for regulating autoimmune responses. It functions by limiting T cell inflammatory responses towards self-cells, preventing autoimmune diseases but at the same time forestalling the immune system from killing cancer cells. PD-1 along with its receptor programmed-cell-death-protein-1-ligand, or PD-L1, forms the programmed cell death pathway which promotes the programmed cell death or apoptosis of antigen specific cytotoxic T lymphocytes in the lymph nodes through self-selection, supporting survival of T regulatory cells by limiting apoptosis events among these cells. It is commonly used as a target for immune checkpoint and monoclonal antibody treatments in certain cancer types, therefore understanding the mechanism of the PD1 pathway is crucial for development of combined immunotherapies and prognosis. Most treatments blocks PD-1 in order to initiate anti-tumor activities by galvanizing T cell activities. However, for certain types of cancer and some patients prone to develop drug resistances, PD-1 related cancer treatment may have unsatisfying result. In this paper, we focus on gathering the mechanism and treatment related with PD-1 pathway. We also discuss the ethics, safety, and side effects of particular drugs utilizing the PD-1 pathway and the promising future for combination therapies.

Keywords: PD-1/PD-L1, Checkpoint Inhibitors, Tumor Suppression, Cancer Therapy.

1. Introduction

The immune system serves a role to recognize and destroy foreign invaders; they are supposed to treat cancer cells as non-self-cells by destroying them. Immune checkpoint inhibitors target and block proteins from some types of immune cells. These proteins are crucial parts of specific pathways or mechanisms found on cells, including T cells, cancer cells, macrophages, etc., that will aid in the progression of certain diseases. These checkpoints keep immune response from being too strong and can keep T cells from killing or recognizing cancer cells. When specific checkpoint blockage works efficiently, immune cells like cytotoxic T cells can kill cancer cells better. There has been a particular focus on antibody therapies that aids to interrupt the PD-1 receptor or the PD-L1 ligand for certain cancer patients ever since the discovery of checkpoint inhibitor therapies. The programmed cell death pathway regulated by these proteins can negatively regulate the immune responses that are responsible by T killer cells or B cells [1]. When activated T lymphocytes release excess interferon-gamma into the tumor microenvironment, it can galvanize the production of PD-L1 protein on the infiltrated T-cells and cancer cells [2]. This specialty is often utilized by tumor cancer cells to avoid antigen-specific T-cell mediated immune responses [3-5]. T lymphocytes are normally activated in the lymph nodes by dendritic cells that traveled from the site of infection, and can then infiltrate the tumor micro-environment. PD-L1, under normal conditions, aids to maintain homeostasis, but when in abundance, can help tumor cells [1]. The completed interaction of PD-L1 protein to B7-1 on CD8 T-cells can deactivates cytotoxic activities, resulting in prolonged progression and survival of certain tumor cells. In such a way, the PD-1 is crucial for cancer by promoting their development and progression by amplifying the cancer survival rates.

The PD-1/PD-L1 checkpoint inhibitor therapies are very different from chemotherapy. These inhibitors are well tolerated with no cell poison, loss of hair, or decline in white blood cells [2]. It has a well-known safety reputation, and the most severe side effects are autoimmune diseases such like pneumonitis, and colitis, which only occur in less than 10% of patients. The more well-known

immune blockage drug is ipilimumab that targets CTLA-4 protein. However, the IAEs incidence of PD-1 pathway related therapies are significantly lower comparing to CTLA-4 blockage therapies, and studies have shown that PD-1 related therapies are generally more reliable and efficient when treating melanoma [5].

2. Mechanism of the Programmed Cell Death-1 pathway

2.1. The structure of BP neural network

The programmed cell death pathway is constructed by PD-1 and PD-L1, which are also referred to respectively as CD279 and CD273. A type I transmembrane protein receptor with a length of 288 amino acids is known as the PD-1 protein. The phenomenon of apoptosis in immune cell lines was seen for the very first time in the laboratory of Tasuku Honjo in 1992, which led to the discovery of the phenomenon [4]. A study that was conducted in vivo using mice that lacked the PD-1 gene indicated that it has a function as a negative regulator of autoimmune diseases. The PDCD1 gene, which is found on chromosome 2, is a 55-kilodalton gene segment that has five exons. The protein in question is encoded by this gene. Naive T-cells found in the lymph nodes are devoid of the PD-1 protein receptor, which is not activated on the T-cell until it has been stimulated by antigen-presenting cells in one of two ways: either through activation of the T cell receptor and MHC peptides or through activation of CD28 and B7 [6-8].



Figure 1. PD-1 pathway for T cell suppression utilized by cancer cells.

PD-L1, which also goes by the names CD273 and B7-H1, serves as a protein receptor for this pathway, and is identified as a B7 family member and is a type 1 transmembrane receptor. The research group led by Liping Chen made the first identification of this protein in 1999. It was found in the B7-H1 gene that is found in humans 9 [3]. Reduces the synthesis of IL-10, which in turn helps regulate the activity of regulatory T cells. The CD274 gene, which is located on chromosome 9, has 7 exons, each of which contains the genetic code for one of the 290 amino acid proteins that are part of the PD-L1 complex. In all, there are three domains, two of which are located outside of the cell and one of which is located inside the cytoplasm. There are just 30 amino acids found in the intracellular domain, and nobody really knows what role they play in the body [2]. When proinflammatory cytokines like IFN-gamma or IL-4 are overproduced, there is typically an increase in the level of the PD-L1 protein.

When the pathway is activated, it inhibits killer T cell activities in various ways, considerably i,pacting IFN-, TNF-, and IL-2 cytokine productions. By blocking early cell differentiation and activation events mediated by CD28 or IL-2, PD-1 pathway can greatly impact early cell development

[7]. It limits T cell activation kinases through SHP2 phosphate activities, and reduces activation of BCl-xL and effector cell function for transcription factors [8]. There has been plenty of success of checkpoint blockage and monoclonal antibody therapies targeting this pathway to treat melanoma, renal cell carcinoma, nonsmall cell lung cancer (NSCLC), and Hodgkin's lymphoma comparing to other potential protein targets or chemo therapies [1]. However, there have also been ICT targeted studies showing atypical negative responses on involved patients, causing hyperprogressive disease (HPD) and pseudoprogressive disease (PPD) [2]. This shows there are still many possibility and incomplete understanding relating to the programmed cell death pathway.

3. FDA Approved Drugs and In Trail Drugs:

3.1. Atezolizumab

The monoclonal antibody known as atezolizumab is derived from a modified form of the IgG1 gene in which the Fc domain has been swapped out. The term MPDL3280 was formerly given to what is now known as. Antibodies that specifically targets PD-L1 are used in order to prevent the elimination of PD-L1 positive T cells from the body. This is done in order to achieve the aforementioned goal [8-9]. By inhibiting the connection between PD-L1 receptor, PD-1 and B7-1 molecules, this treatment eliminates cancerous cells and stimulates the immune system to fight the disease. However, since it does not have any effect on the PD-L2 protein, it does not serve as a target for that protein. The PD-L1 protein is prevalent not just on cancer cells, where it is strongly expressed, but also on immune cells that have the ability to penetrate malignant tissue and is highly expressed there as well. In addition, the synthesis of it may be traced back to cancer cells [8-9]. In addition, significant quantities of the PD-L1 protein are expressed by the great majority of cancer cells. The preliminary research with atezolizumab revealed that it had an effect on the levels of cytokines. The number of functional CD8+ T cells in the body increased as a direct consequence of this. Researchers have discovered that the anti-cancer medication atezolizumab may boost T cell-mediated immunity [10]. It's possible that the levels of tumor microenvironment inhibitory signal molecules will need to be decreased in order to accomplish this aim.

In October 2016, patients with metastatic non-small cell lung cancer whose condition worsened during or after therapy with a drug containing platinum were given the go-ahead to use atezolizumab as a therapeutic alternative [11]. Patients must have had their condition worsen during or after treatment with the platinum-containing drug. These patients had previously been treated with medications based on platinum [11]. A greater percentage of those who generally have longer life spans reaped the benefits. In addition, the primary objective of the BIRCH phase II study was accomplished, which was to demonstrate that atezolizumab was effective in reducing tumors in as many as 22 percent of patients whose cancer had progressed after receiving one or more prior chemotherapy regimens, some of which contained platinum. This objective was successfully accomplished. In order to accomplish this aim, it was necessary to provide evidence that treatment with atezolizumab effectively decreased the size of the tumor in at least 22 percent of patients [3]. The patients described above had never participated in any kind of treatment. During the Phase III OAK research, patients with advanced non-small cell lung cancer received a treatment regimen consisting of a combination of atezolizumab and docetaxel. In order to assess whether or not a certain treatment was worthwhile, researchers considered both its advantages and disadvantages [5]. The encouraging results obtained from the POPLAR and BIRCH clinical trials served as a driving force for our inquiry. According to our findings, the adverse impacts may be roughly divided into two categories: mild and moderate. This finding is in line with the findings of other studies. Both the population that received the treatment that was intended (referred to as ITT) and the population that expressed PD-L1 (referred to as IHC 1/2/3) were successful in meeting the primary endpoint of the OAK trial, demonstrating that atezolizumab improved overall survival in comparison to docetaxel [7].

3.2. Avelumab

The human IgG1 monoclonal antibody known as avelumab has the ability to bind not just PD-L1, but also other proteins [4]. By locking the interaction of PD-L1 molecules with inhibitory T cell receptors such as PD-1 and B7-1 the immune system can better initiate adaptive immune response utilizing T cells, increase T cell activation rates, and increase certain cytokine production [4]. The clinical use of avelumab was made feasible as a direct result of the research conducted by Merck & Co., Inc. Injections of the medication avelumab are one potential method of administering treatment for metastatic Merkel cell carcinoma (MCC), a kind of skin cancer that may affect persons of any age but most often affects those who are older than 12 years old [7]. When injected into patients whose cancer has reappeared after or within 12 months of undergoing platinum chemotherapy treatments, avelumab may also be effective in treating urothelial carcinoma, which is a disease that affects the bladder and the urinary system. A previous treatment history including platinum-based chemotherapeutics is required for this hypothetical situation. Anti-cancer monoclonal antibodies, such as avelumab, function by attaching to a protein that is nearly entirely expressed on the surface of cancer cells. This is how they combat the disease. When compared to atezolizumab and durvalumab, the crystallizable fragment (Fc) region of avelumab is most comparable to that of IgG1, which is also the case with durvalumab. Therefore, it has the potential to bind to Fc receptors on natural killer cells and trigger antibody-dependent cell-mediated cytotoxicity against tumors in vitro (ADCC) [9]. Therefore, avelumab has the ability to kill cancer cells through boosting the adaptive and innate immune systems of the body.

3.3. BMS-936559

Biogen, Inc. is responsible for the development of the humanized IgG4 monoclonal antibody BMS-936559. Because of the high binding affinity of this antibody and the possibility that it would be useful in the battle against cancer, it was created. The fundamental objective is to separate PD-L1, PD-1, and CD80 from one another and sever their connection to one another. Many individuals continue to refer to it by its previous designation, MDX-1105, despite the fact that its official name has been changed to BMS-936559 [7]. There may be reservoirs of the virus in the body even when the viral load is low and the patient is taking a combination of antiretroviral medications. This is because HIV does not completely eradicate from the body. This is due to the fact that there is a possibility that the virus may not respond to treatment (cART). A number of clinical studies have been carried out in order to investigate BMS-936559 for any possible anti-cancer properties it may have. In this study, the immunotherapeutic efficacy, pharmacokinetics (PK), and safety of a single dose of BMS-936559 (administered through intravenous infusion) were investigated in HIV-positive individuals whose viral load had been adequately suppressed with a combination of antiretroviral medications (cART) [2]. In addition, we will explore whether or whether BMS-936559 can inhibit HIV reservoirs that are dormant. 207 people with advanced solid tumors participated in the study to investigate the efficacy and safety of BMS-936559 as a therapy. A dose-escalation technique was used to gradually increase the amount of the medication that each patient received throughout the course of their treatment (0.3-10 mg/kg every 14 days, 3 times every 6-week course, for a maximum of 16 cycles) [4-6]. In spite of the fact that the medication was generally well accepted, some individuals had unwelcome side effects such as infusion reactions, lethargy, diarrhea, arthralgia, rash, nausea, itching, and headaches [7]. The level of exposure to the chemical required before symptoms appeared was rather high. Overall, the treatment was successful for seven percent of patients with advanced cancers, and these patients survived the treatment for an average of twelve weeks. These individuals were found to be suffering from a wide range of cancers, including melanoma and renal cell carcinoma, according to their diagnoses [5-7].

3.4. BGB-A333

The IgG1 subclass is included inside the humanized monoclonal antibody BGB-A333. If a chemical can bind to PD-L1 and prevent the protein from binding to its receptor, PD-1 on T cells,

then T cell inactivation may be reversed, T cell proliferation may be increased. All of these effects may be achieved against PD-L1-expressing cancer cells. When used to cancer cells that express PD-L1, any or all of these effects are a distinct possibility [11]. The combined therapy of BGB-A333 (1350 mg IV Q3W) and tislelizumab was administered to these individuals (200 mg IV Q3W). Patients must fulfill all of the following requirements in order to be considered for participation in the research: they must have advanced or metastatic UC; they must have an ECOG performance level of 1; they must not have responded to chemotherapy that was based on platinum; and they must have exhausted all other possible therapeutic options. According to the findings of RECIST v1.1, the objective response rate was the most important result. Monitoring adverse events for the purpose of conducting a safety assessment was one of the important tertiary objectives [7-9]. Other important tertiary goals were doing an analysis of progression-free survival using Kaplan-Meier techniques and an evaluation of response duration using RECIST v1.1. There is Some Evidence That Protein 1 Contributes to the Development of Disease (PD-L1) A medicine that blocks the capacity of PD-ability L1s to trigger cell death not only extends the lifetimes of activated CD8+ T lymphocytes but also stimulates their proliferation and increases their number [11]. This is accomplished by preventing the pathway that leads to the death of cells.

3.5. CK-301

Researchers created a human IgG1 monoclonal antibody that they called CK-301. This antibody binds to PD-1 and B7.1 receptor, which allowed them to combat the effects of PD-L1 [2]. CK-301, like avelumab, exhibits a functioning Fc domain and has the capacity to induce apoptosis in PD-L1+ cell types such as lymphoma cells. CK-301 also possesses these characteristics. According to the findings of our study, which used the mixed lymphocyte response culture method, primary human T cells have the capability to upregulate the production of IFN-gamma, and PD-L1 demonstrated binding affinity of less than a nanomolar. Both of these fields have seen significant advancements in terms of development (MLR). Researchers are seeking for patients with advanced malignancies to take part in an intravenous monotherapy trial of CK-301 [2].

3.6. CS-1001

CS-1001 is the first full-length IgG4 monoclonal antibody, and its mechanism of action involves binding to PD-L1. This prevents PD-L1 from interacting with PD-1, which in turn leads to an increase in T cell-mediated immune responses against cancer. To be more specific, it decreases the efficiency of the interaction that takes place between the two molecules. The CS1001 monoclonal antibody was developed to have an action that is similar to that of the body's own immunoglobulin G4, which lowers the risk of immunogenicity as well as the possibility of other negative outcomes (IgG4) [12]. Patients who had already been diagnosed with metastatic cancer participated in the study's phase I, during which the anticancer activity of CS-1001 and its pharmacokinetics were analyzed (PK). The medicine was administered to the five groups once every three weeks, beginning at a dose of 3 mg/kg and progressing through doses of 10 mg/kg, 20 mg/kg, 40 mg/kg, and 1200 mg [8]. Despite its favorable safety profile and linear PK profile, CS-1001 was associated with a number of treatment-emergent adverse events (AEs) that were observed. Anemia of grade 1/2, nausea, reduced appetite, leucopenia, and proteinuria were some of the adverse effects that were observed. Its pharmacokinetic profile was linear, much as that of CS-1001, which was comparable to its profile. In addition to this, it had a success rate of 58% when it came to preventing cancer.,

3.7. Durvalumab

Durvalumab is IgG1 monoclonal antibody, which was developed to recognize and bind to programmed death ligand 1. It is also known by its previous name, MEDI4736. To put it another way, a chemical prevents antibodies from carrying out their intended function of killing T cells that express PD-L1. When administered at concentrations that are subnanomolar, durvalumab is able to inhibit PD-activity [11]. L1's Through the creation of an innovative xenograft model in which human T cells

are co-implanted, it has been demonstrated that durvalumab significantly inhibits the progression of human cancers in vivo. This was accomplished with the help of human T cells [1]. Due to the positive findings obtained from these tests on humans, the durvalumab treatment was rushed into clinical testing. Durvalumab's pharmacokinetics, safety, and patients' ability to tolerate it were evaluated during Phase I in a total of 32 people with advanced solid cancers. In upcoming research, participants will receive an injection of 10 mg/kg of durvalumab every two weeks. Patients who have advanced urothelial bladder cancer have been given durvalumab as part of an ongoing, open-label, dose-escalation and dose-expansion study. This research has shown that the drug is clinically active in these patients. For up to a year of treatment, taking 10 mg/kg of durvalumab every two weeks was well tolerated, there was no progression of the cancer, there was no need for additional anti-cancer treatment, and there were no severe side effects [11]. In the same way that other PD-L1 inhibitors do, durvalumab caused drowsiness, diarrhea, and an inability to appetite. Response rates were strong and long-lasting, reaching 27.6% and 5.1%, respectively, in patients who had high PD-L1 expression, patients who had low PD-L1 expression, and patients who had negative PD-L1 expression [13].

3.8. Envafolimab

Envafolimab (KN 035 or ASC 22), is the first nanobody that was created by integrating an anti-PD-L1 domain with the Fc portion of a human IgG1 antibody. T cells are prepared to participate in anti-cancer immune surveillance and response when the PD-interaction L1's that they normally have with PD-1 are blocked. In competitive ELISA biochemical experiments, the IC50 value for envafolimab's ability to disrupt the interaction between PD-L1 and PD-1 was determined to be 5.25 nm. Envafolimab, when given subcutaneously, has been proven in experiments conducted on animals to be more effective in penetrating tumor tissue and to have less immunogenicity than previous PD-L1 inhibitors [3]. These findings are based on the results of the research. Researchers have shown that a chemical may promote the production of T cell cytokines as part of a mixed lymphocyte response in a manner that is dependent on both the dosage and the amount of time exposed to the chemical [11]. Experiments with xenograft animals showed that dosages of envafolimab ranging from 0.1 to 0.5 mg kg1 had a significant amount of anticancer effect. Patients with advanced solid tumors who participated in a phase I dose-escalation trial for Envafolimab reported a side effect profile that was manageable and positive early signs of the potential for the drug to aid anticancer treatment [9]. The mice received subcutaneous injections on a weekly basis of 0.1, 0.3, 1.0, 2.5, 5.0, and 10.0 mg/kg as their doses. In this investigation, there was no indication of delayed symptom onset (also known as DSO). These findings have led to the launch of two clinical trials in China: one for patients with advanced solid tumors that have high levels of microsatellite instability (MSI-H), and the other for those who have cancer of the biliary system (cholangiocarcinoma) [13].

4. Combination Therapies

PD-1 and CTLA-4 inhibitors are beneficial in the treatment of lung cancer. Research is being conducted to assess the proportion of people whose tumors have a lower mutational burden and who also have better objective responses, benefits that last for a longer period of time, and a longer progression-free survival time [7]. It is possible that the amount of mutations that are present in a tumor might be a key genetic element in determining whether or not a patient will respond positively to a treatment plan that incorporates immunotherapies that block PD-1 and CTLA-4.

Anti-PD-1/PD-L antibodies are currently being investigated in a variety of settings, including preclinical as well as clinical research. In the clinical research, tumor models are being utilized, whereas in the preclinical research, additional checkpoint proteins are being utilized in conjunction with anti-PD-1/PD-L antibodies. T-cell checkpoint proteins include lymphocyte activation gene 3, T cell immunological receptor with Ig and ITIM domains (TIGIT), and V-domain Ig repressor of T-cell activation. Other proteins that function in this capacity include V-domain Ig repressor of T-cell activation (VISTA) [11]. We were able to improve immune responses against cancer by concentrating

on the TIM-3 pathway, TIGIT, and VISTA at the same time [11]. In addition, the PD-1 pathway was involved in this process. Anti-programmed death 1 (PD-1) and PD-L1 antibodies were employed in conjunction with anti-co-stimulatory molecule (CoS) antibodies in tumor models in order to stimulate a stronger immune response. This was accomplished by combining the three types of antibodies. Inducible T cell costimulator (ICOS), TNF receptor superfamily member 4, and TNF receptor superfamily member 9 were the targets of these antibodies. We were successful thanks to the combined efforts of all three of these antibodies. When a large number of checkpoints are blocked simultaneously at modest dosages, it seems that the therapeutic benefits are increased to their maximum potential [2-4]. According to several studies, the effectiveness of anti-CTLA4 and anti-PD1/PDL1 antibodies on their own ranges between 20 and 25 percent [12]. It is possible that the success rate will reach 60 percent if anti-CTLA4 and anti-PD1/PDL1 antibodies are both given concurrently. It is possible that the effectiveness of the treatment might be improved by combining PD1-blocking antibodies with agonistic antibodies that activate the costimulatory receptor glucocorticoid-induced tumor necrosis factor receptor (GITR). Wang et al. demonstrated, via the use of the MC mouse colon cancer cell line, that anti-PD-1+ anti GITR had a much greater anticancer impact in mice than each antibody alone did when evaluating the effectiveness of the treatment against cancer [4-6]. There is a synergistic impact of anti-PD-1+ and anti-GITR treatment when CD8+ T cells are present. CD8+ T cells have the potential to eliminate cancer cells on the spot, and they may also seek out and attract new malignant immune cells from inside tumors. This may happen when CD8+ T cells are present in the tumor. For the purpose of in vivo combination treatment, Wang et al. constructed a reactive oxygen species-reactive scaffold utilizing a PD1/PDL1 checkpoint inhibitor in conjunction with gemcitabine (GEM). In tumor-bearing mice treated with the aPDL1-GEM scaffold, immunogenic tumor phenotype, increased immune-mediated tumor regression, and reduced tumor recurrence following initial resection were observed. In order to treat a mouse model of cancer, Gao et al. used an anti-PD1 antibody in conjunction with an HDAC2 inhibitor [2]. When HDAC2 inhibitors were delivered in conjunction with anti-PD1 antibodies, as opposed to anti-PD1 treatment alone, there was a substantial reduction in tumor progression and an increase in survival rates. This was in comparison to the anti-PD1 therapy group [7].

Inflammation may occur in the skin, intestines, liver, pancreas, lungs, and hypophysis when anti-CTLA-4 or anti-PD-1/PD-L antibody treatment is administered. It is abundantly obvious that the toxicity and adverse effects that are associated with checkpoint combination therapies stand out [3]. Almost all melanoma patients who are treated with an antibody combination consisting of anti-PD-1/PD-L1 and anti-CTLA-4 will have immune-related side effects (irAEs). As a consequence of this, it is probable that more study into the mechanisms of these checkpoint treatments is required in order for us to reduce the toxicity of these medications [15].

The mutational load is one of these factors that has the potential to impact a patient's response to PD-1/PD-L1 treatment [16]. Melanoma is a well-known "hot tumor" due to the large number of mutations that may be utilized to identify neoantigens and the remarkable therapeutic advantages of checkpoint medication. This makes melanoma an attractive target for cancer research. Melanoma is a cancer that has a high mortality rate, therefore this makes it an important subject for research among medical professionals [17]. The use of whole-exome sequencing in the treatment of non-small-cell lung cancer (NSCLC) has shown that changes in the genetic landscape of the tumor are predictive of how the patient would react to treatment with anti-PD-1 antibodies. Anti-PD-1 antibody treatment may be of help to patients with colon cancer whose tumors develop mutant neoantigens that are capable of being identified by T cells [18]. This is only a hypothesis, though. The reason for this is because the cancer cells in their bodies are unable to repair DNA mismatches [17]. Neoantigens are components of all tumor vaccines, regardless of whether the vaccine was produced using entire cancer cells, cancer cell fragments, or merely tumor antigens. However, there have been some issues discovered with vaccinations against tumors that are based on neoantigens. When is the most convenient time to have all of your vaccinations at the same time? Should immunizations be given to children, and if so, at what age? Which patients are most likely to make the greatest progress, and on

the basis of what criteria should we evaluate them? In a study that included patients with recurrent melanoma who had previously received vaccines targeting their specific tumor neoantigens, treatment with anti-PD-1 medication led to total regression of tumors and proliferation of T cells that identified the neoantigens. This was found in patients who had received vaccines targeting their specific tumor neoantigens. While more clinical research and in-depth investigation of the underlying processes are necessary, the results presented here give a strong foundation on which to build [19].

Chemotherapy induces DNA damage in tumor cells, which therefore causes the cells to cease proliferating and eventually die. Radiation treatment, on the other hand, causes dendritic cells to be stimulated into secreting type I interferon, which results in a significant increase of tumor-specific T lymphocytes [2-20]. These therapies, when combined, have the potential to eradicate any residual tumor tissue. In response to therapy, these tactics may promote the synthesis of tumor neoantigens, which may result in a hot TME; however, further mechanistic study is necessary to support this concept [21]. These two approaches have demonstrated promising outcomes in clinical studies when combined with antibodies that target PD-1/PD-L. Antibodies directed against programmed death receptor 1, also known as PD-1, and programmed death receptor L1, also known as PD-L1, showed promise in the treatment of non-small cell lung cancer, with less immune-related side effects. Radiation therapy plus dual checkpoint suppression with CTLA-4 and PD-L1 helped patients with metastatic melanoma see a considerable reduction in the size of their tumors [19]. The war against cancer has made significant progress, but there is still a great deal of work to be done, and it will need a significant amount of funding to support more clinical research that aims to determine the most effective methods and times to deliver medicines [17].

This suggests that PD blockade, along with other immune inhibitor blockades such as CTLA-4, TIM-3, LAG3, TIGIT, CD244m, and CD160, will be employed in the future. Further, it works well with many different types of immunostimulators. Additional kinase inhibitors, such as those directed against Braf, etc., may be employed in this approach as well [21]. Cancer treatments such as those that interfere with angiogenesis, radiation, HDAC inhibitors, cancer vaccines, oncolytic viruses, and CAR-T therapies, among others, are all being explored both alone and in different combinations.

5. Conclusions

In recent years, cancer immunotherapy that targets PD-1 or PD-L1 has demonstrated promising effects against a variety of tumor types. These findings have been obtained against a wide variety of cancers. Despite the fact that there is still a great deal that scientists do not understand about the PD-1/PD-L1 signaling pathway, it is anticipated that medicine that blocks PD-1/PD-L1 will soon become the usual approach to cancer immunotherapy. It will be essential to demonstrate the clinical effectiveness of these medications by employing tailored markers in directing anti-PD treatment alone or in combination with other targets. Although additional research is required to shed light on these essential topics, it will also be necessary to conduct this research. Several confirmatory phase III studies have failed to reach primary goals, such as PFS or OS, despite early/accelerated FDA clearance. The investigation and development of immunotherapies have only just lately gotten under way. Additional research is required into a variety of areas, including predictive biomarkers, mechanisms of resistance, the expression threshold for PD-L1, improved biomarker assays, immune-related harm, and treatment duration. The Food and Drug Administration has only given its approval to three of the numerous potential PD-L1 inhibitors that are now undergoing clinical testing. PD-L1 alone still have very promising potentials, future studies should focus on the most optimizing result for combined therapies.

References

[1] Keir ME, et al. PD-1 and its ligands in tolerance and immunity. Annu Rev Immunol. 2008; 26:677–704.

[2] Keir ME, et al. PD-1 and its ligands in T-cell immunity. Curr Opin Immunol. 2007;19(3):309–14.

[3] Ribas A. Tumor immunotherapy directed at PD-1. New England of Journal of Medicine. 2012.

[4] Ishida Y, et al. Induced expression of PD-1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death. EMBO J. 1992;11(11):3887–95.

[5] Chen J, et al. Regulation of PD-L1: a novel role of pro-survival signalling in cancer. Ann Oncol. 2016;27(3):409–16.

[6] Nurieva R, et al. T-cell tolerance or function is determined by combinatorial costimulatory signals. EMBO J. 2006;25(11):2623–33.

[7] Terme M, et al. IL-18 induces PD-1-dependent immunosuppression in cancer. Cancer Res. 2011;71(16):5393–9.

[8] Francisco LM, et al. PD-L1 regulates the development, maintenance, and function of induced regulatory T cells. J Exp Med. 2009;206(13):3015–29.

[9] Zou W, Chen L. Inhibitory B7-family molecules in the tumour microenvironment. Nat Rev Immunol. 2008;8(6):467–77.

[10] Dong H, et al. Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion. Nat Med. 2002;8(8):793–800.

[11] Lee SK, et al. IFN-gamma regulates the expression of B7-H1 in dermal fibroblast cells. J Dermatol Sci. 2005;40(2):95–103.

[12] Diggs LP, et al. Utility of PD-L1 immunohistochemistry assays for predicting PD-1/PD-L1 inhibitor response. Biomark Res. 2017; 5:12.

[13] Rebelatto MC, et al. Development of a programmed cell death ligand-1 immunohistochemical assay validated for analysis of non-small cell lung cancer and head and neck squamous cell carcinoma. Diagn Pathol. 2016;11(1):95.

[14] Powles T, et al. MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer. Nature. 2014;515(7528):558–62.

[15] Fehrenbacher L, et al. Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial. Lancet. 2016;387(10030):1837–46.

[16] Sharma P, et al. The future of immune checkpoint therapy. Science. 2015; 348:56.

[17] Ribas A, et al. Cancer immunotherapy using checkpoint blockade. Science. 2018; 359:1350–55.

[18] Ahmadzadeh M, et al. Tumor antigen-specific CD8 T cells infiltrating the tumor express high levels of PD-1 and are functionally impaired. Blood. 2009; 114:1537–44.

[19] Fourcade J, et al. Upregulation of Tim-3 and PD-1 expression is associated with tumor antigen-specific CD8+ T cell dysfunction in melanoma patients. J Exp Med. 2010; 207:2175–86.

[20] Wang J, et al. Fibrinogen-like protein 1 is a major immune inhibitory ligand of LAG-3. Cell. 2019; 176:334–47. e12.

[21] Sanmamed MF, et al. A paradigm shift in cancer immunotherapy: from enhancement to normalization. Cell. 2018; 175:313–26.